Primary malignant lymphomas of the central nervous system: radiotherapy results in 12 cases.
- Author:
Chang Ok SUH
1
;
John J K LOH
;
Gwi Eon KIM
;
Byung Soo KIM
;
Joong Uhn CHOI
;
Sang Sup CHUNG
;
Kyu Chang LEE
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Brain neoplasm; non-Hodgkin's lymphoma; lymphoma; radiation therapy
- MeSH: Adult; Central Nervous System Diseases/radiography/*radiotherapy; Combined Modality Therapy; Female; Human; Lymphoma/radiography/*radiotherapy; Male; Middle Age; Support, Non-U.S. Gov't; Tomography, X-Ray Computed
- From:Yonsei Medical Journal 1989;30(1):54-64
- CountryRepublic of Korea
- Language:English
- Abstract: Twelve patients with primary lymphomas of the central nervous system were treated in the Department of Radiation Oncology, Yonsei University College of Medicine, between 1976 and 1987. There were seven males and five females ranging from 19 to 63 years of age. They had single (6 cases) or multiple (6 cases) discrete intracerebral nodules. All patients were treated with radiation therapy. Surgical resection was performed in five cases and intrathecal chemotherapy with methotrexate was performed in seven cases after radiotherapy. All patients except one had received whole brain irradiation with a median dose of 4000 cGy. The radiation dose for a primary tumor was 4800-6000 cGy (median 5560 cGy). Initial response to radiation was excellent with a 91.7% complete response rate, but late recurrences were noted and the median survival was 42.3 months. Intracranial recurrences were observed in two patients who received less than 4000 cGy to the whole brain without intrathecal chemotherapy. Although intracranial recurrence was not seen in the patients receiving intrathecal chemotherapy after radiation, a high incidence of necrotizing leukoencephalopathy was noted. High dose irradiation with a minimum of 4000 cGy to the whole brain and more than 5000 cGy to the primary tumor is recommended for the treatment of primary CNS lymphomas. Combined use of chemotherapy should be carefully attempted because of the increased toxicity.
